Given Imaging Announces The Results Of Two Recent Studies Underscoring The Economic Value And Clinical Utility Of PillCam(R) ESO In Managing Upper GI Bleeding In The Emergency Department Setting

- Cost analysis shows PillCam ESO saves more than $10,000 versus a scoring-based risk stratification strategy for patients at low risk -

- PillCam ESO is significantly more effective than nasogastric tubes in detecting upper GI bleeding and comparable to EGD in identifying upper GI ulcerations -

SEATTLE, Oct. 21, 2013 (GLOBE NEWSWIRE) -- Given Imaging Ltd, (Nasdaq:GIVN), a world leader in GI medical devices and pioneer of capsule endoscopy, today announced results from two studies highlighting the clinical and economic benefits of PillCam ESO in the evaluation of patients with acute upper gastrointestinal (GI) bleeding in the emergency department setting. Both studies were presented during the American College of Emergency Physicians (ACEP) Scientific Assembly, the largest annual international emergency medicine conference, which took place in Seattle, Washington, October 14-17, 2013.

"The Cost-Effectiveness Analysis of Video Capsule Endoscopy Compared to Other Strategies to Manage Acute Upper Gastrointestinal Hemorrhage in the Emergency Department " (poster 65), presented by Andrew Meltzer, M.D., George Washington University Medical Center, Washington, DC and colleagues, analyzed the cost variances among diagnostic strategies including PillCam capsule endoscopy, risk stratification using the Glasgow-Blatchford score, nasogastric tube placement and an admit-all strategy. They found that, for patients at low risk of requiring endoscopic hemostatic intervention, capsule endoscopy was the dominant strategy with a cost of $5,691. These metrics were significantly stronger than all of the remaining strategies including the nasogastric tube strategy with added incremental cost of $2,469, the risk stratification strategy with an incremental cost of $10,695 and the admit-all strategy with an incremental cost of $17,076 versus capsule endoscopy. For moderate risk patients, capsule dominated an admit-all strategy with a cost of $9,190 versus an added incremental admit-all cost of $13,098. Based on this analysis, researchers concluded that capsule endoscopy may be cost-effective for low and moderate risk patients presenting with upper GI bleeding to the emergency department.

Although the risk stratification strategy utilizing the Glasgow-Blatchford score is recommended, neither this strategy nor the nasogastric tube are utilized by most emergency departments. A 2012 National Institute of Health funded study found that one in every five Americans has at least one visit to the emergency department per year 1 , with a large number of patients depending on the emergency department to obtain acute medical care, resulting in increased healthcare costs.

"PillCam's unique ability to directly visualize the upper GI tract non-invasively to identify the presence or absence of a hemorrhage could offer a novel and cost-effective approach in the emergency department setting," said Dr. Meltzer. "The cost savings on a per-patient basis could have a positive impact on the economic outcomes health care systems are striving for today."

If you liked this article you might like

Covidien Looks Fully Valued

Covidien Scopes Out Medical Technology Growth

Jim Cramer's 6 Stocks in 60 Seconds: CELG CRM ATHN LULU LMT GIVN (Update 1)

Stocks Inch Higher as Chinese Exports Boost Global Markets

Chinese Data Lead Off U.S. Market Action